Patents
Literature
8 results about "Thiolase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Thiolases, also known as acetyl-coenzyme A acetyltransferases (ACAT), are enzymes which convert two units of acetyl-CoA to acetoacetyl CoA in the mevalonate pathway. Thiolases are ubiquitous enzymes that have key roles in many vital biochemical pathways, including the beta oxidation pathway of fatty acid degradation and various biosynthetic pathways. Members of the thiolase family can be divided into two broad categories: degradative thiolases (EC 2.3.1.16) and biosynthetic thiolases (EC 2.3.1.9). These two different types of thiolase are found both in eukaryotes and in prokaryotes: acetoacetyl-CoA thiolase (EC:2.3.1.9) and 3-ketoacyl-CoA thiolase (EC:2.3.1.16). 3-ketoacyl-CoA thiolase (also called thiolase I) has a broad chain-length specificity for its substrates and is involved in degradative pathways such as fatty acid beta-oxidation. Acetoacetyl-CoA thiolase (also called thiolase II) is specific for the thiolysis of acetoacetyl-CoA and involved in biosynthetic pathways such as beta-hydroxybutyric acid synthesis or steroid biogenesis.
Production of fatty alcohols in peroxisome of yarrowia lipolytica
PendingUS20260043055A1Antibody mimetics/scaffoldsMicroorganism based processesHeterologousNucleotide
The invention provides a recombinant Yarrowia lipolytica. The recombinant Yarrowia lipolytica comprises a heterologous polynucleotide encoding a fusion protein. The fusion protein comprises a first amino acid sequence and a second amino acid sequence. The first amino acid may be homologous to the amino acid sequence of 3-ketoacyl CoA thiolase (3KAT), The second amino acid sequence may be homologous to the amino acid sequence of a fatty acyl-CoA reductase (FAR). Also provided is a method for producing one or more fatty alcohols by the recombinant Yarrowia lipolytica and a method for preparing the recombinant Yarrowia lipolytica.
Owner:UNIVERSITY OF DELAWARE
Escherichia coli engineering bacteria with high n-hexanoic acid yield and construction method and application thereof
This invention belongs to the fields of fermentation and genetic engineering technology, and provides a high-yield hexanoic acid-producing engineered *Escherichia coli* strain, its construction method, and its applications. This engineered strain is *Escherichia coli*... E. coli w3110 was the starting strain, overexpressing the acetyl-CoA transferase gene. act and β-ketothiolase gene bktB Overexpression of trans-enoyl-CoA reductase gene ter 3-Hydroxybutyryl-CoA dehydrogenase gene hbd, and 3-hydroxybutyryl coenzyme A dehydratase gene crt Or, simultaneously not expressing the pyruvate formate lyase gene. pflB or lactate dehydrogenase gene ldhA This engineered bacteria can convert glucose into hexanoic acid, a high-value product, with a yield of 4.968 g / L after 18 hours of fermentation. It adopts aerobic fermentation, resulting in rapid cell growth, a short fermentation cycle, and a high acid production rate. The fermentation process is simple, easy to control, and has low production costs, which is conducive to its promotion and application in industrial production.
Owner:SHANXI NORMAL UNIV
Genetically engineered bacteria as a chassis host for high yield terpenoid production
PCT designated stageWO2025217176A9OxidoreductasesAcyltransferasesDiphosphomevalonate decarboxylaseOperon
Described herein are compositions and methods for generating a chassis for high-capacity production of different classes of high-value terpenoids. The chassis is a microorganism host that expresses a first operon comprising a modified ribosomal binding site, a Hmg-CoA reductase (HmgR) polypeptide, a 3-hydroxy-3-methylglutaryl CoA synthase (HmgS) polypeptide, and a β-ketothiolase (PhaA) polypeptide; and a second operon comprising a modified ribosomal binding site, a mevalonate kinase (MvK1) polypeptide, a phospho-mevalonate kinase (MvK2) polypeptide, and a diphosphomevalonate decarboxylase (MvD) polypeptide.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV
Composition for preventing or treating cancer having resistance to anticancer agents
PCT designated stageWO2026135396A1Organic active ingredientsAntineoplastic agentsChemotherapeutic drugsPharmaceutical drug
The present invention relates to a composition for preventing or treating cancer having resistance to anticancer agents and, more specifically, to a pharmaceutical composition for preventing or treating resistant cancer, comprising a 3-ketoacyl CoA thiolase (ACAA) inhibitor and a carnitine acylcarnitine carrier (CAC) inhibitor and inhibiting the regrowth of cancer having resistance to anticancer agents. It is has been identified that the composition comprising the 3-ketoacyl CoA thiolase (ACAA) inhibitor and the carnitine acylcarnitine carrier (CAC) inhibitor, of the present invention, effectively inhibits the regrowth of cancer cells and tumors having resistance to various anticancer agents, and thus can be effectively used for the prevention or treatment of cancer having resistance to anticancer agents.
Owner:NEW CANCER CURE BIO CO LTD
Kit for catalyzing Friedel-Crafts acylation reaction by enzyme method, application and preparation method
The invention discloses a kit for catalyzing Friedel-Crafts acylation reaction through an enzyme method, application and a preparation method. The kit for catalyzing the Friedel-Crafts acylation reaction by the enzyme method comprises 1) a Friedel-Crafts acylation reaction buffer solution and 2) a thiolase complex MucABC or a functional fragment and a variant thereof. The kit for catalyzing the Friedel-Crafts acylation reaction does not depend on coenzyme A compounds as acyl donors, and can realize regional specific C-acylation modification on various lactam compounds by taking acyl phenyl esters with different chain lengths as the acyl donors under mild conditions; a novel green and efficient biological catalysis tool is provided for Friedel-Crafts acylation reaction, and the method has important value and significance for drug synthesis and chemical production.
Owner:SHENZHEN BAY LAB
Microorganism with improved production level of p-coumaric acid or p-coumaric acid derivative, and construction method and application thereof
The application discloses a kind of p-coumaric acid or p-coumaric acid derivative production level improved microorganism and its construction method and application, comprising: the genetic target point related to p-coumaric acid metabolic pathway of microorganism is reformed, target point is 4-coumaroyl coenzyme A ligase, hydroxycinnamoyl coenzyme A hydratase lyase, hydroxyacyl coenzyme A dehydrogenase, beta-ketoacyl-coa thiolase, 3- (aryl) propenoate reductase one or more than two combinations, reformation is removed the partial activity or all activity of p-coumaric acid metabolic pathway related genetic target point.The application reduces the degree of degradation of p-coumaric acid by microorganism by reformation p-coumaric acid metabolic pathway related genetic target point, to improve the yield and / or production efficiency of p-coumaric acid and p-coumaric acid derivative produced by microorganism.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Recombinant saccharomyces cerevisiae strain for producing cannabinoid phenolic acid at high yield by using sugar as well as construction method and application of recombinant saccharomyces cerevisiae strain
PendingCN121873991AAvoid the bottleneck of caproic acid toxicityFungiHydrolasesEnzyme GeneGeranyl pyrophosphate
The invention relates to the technical field of metabolic engineering, in particular to a recombinant saccharomyces cerevisiae strain for producing cannabinoid phenolic acid at high yield by using sugar as well as a construction method and application of the recombinant saccharomyces cerevisiae strain. According to the invention, firstly, reverse beta-oxidation pathway genes ReBktB, CnPaaH1, CaCrt and TdTer are introduced, so that the problem that cannabinoid phenolic acid biosynthesis depends on a hexanoic acid substrate is solved; and then the gene GAL80 of the GAL4 inhibitory protein is knocked out, and the GAL4 is over-expressed, so that the overall expression level of the pathway is up-regulated. Then, a mercaptase gene Ckth1A and a hydroxyacyl coenzyme A dehydrogenase gene Ckhbd1 are introduced, so that the supply of the hexanoyl coenzyme A is improved. Furthermore, the endogenous farnesyl pyrophosphate synthetase gene ERG20 is down-regulated, and the consumption of geranyl pyrophosphate by a branch path is reduced. Finally, the expression level of part of genes in saccharomyces cerevisiae cells is regulated and controlled through gene editing, and the purposes of synthesizing cannabinoid phenolic acid from the beginning by using saccharomyces cerevisiae and taking sugar as a substrate and improving the yield of cannabinoid phenolic acid are achieved.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI +1
A method for metabolically engineering brewer's yeast to produce limonene and its derivatives
ActiveCN116515658BPolypeptide with localisation/targeting motifFungiIsopentenyl pyrophosphateOxidative enzyme
This invention discloses a method for metabolically engineering Saccharomyces cerevisiae to produce limonene and its derivatives, belonging to the field of biotechnology. The recombinant Saccharomyces cerevisiae uses a Saccharomyces cerevisiae strain with integrated cytochrome P450 oxidase and CPR genes from Salvia miltiorrhiza as the chassis cell. The following genes, with the nucleotide sequence ePTS linked to the 3' end of each gene, are overexpressed: acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase (tHMGR), mevalonate kinase, phosphate mevalonate kinase, diphosphate mevalonate kinase, isopentenyl pyrophosphate isomerase, and farnesyl pyrophosphate synthase, as well as a truncated limonene synthase from Spearmint. After 120 h of shake-flask fermentation, the recombinant strain HY-PER-03 produced 86.74 mg / L of limonene, while S. cerevisiae HY-PA-01 produced 4.42 mg / L of perillic acid.
Owner:JIANGNAN UNIV